GILEAD SCIENCES ($GILD) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of $2.03 per share, beating estimates of $1.95 by $0.08. The company also reported revenue of $6,960,000,000, missing estimates of $7,051,017,984 by $-91,017,984.
Stock price change since market close: -3.24%
You can see Quiver Quantitative's $GILD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
GILEAD SCIENCES Insider Trading Activity
GILEAD SCIENCES insiders have traded $GILD stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 13 sales selling 291,280 shares for an estimated $40,977,655.
- JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 9 sales selling 68,000 shares for an estimated $9,442,901.
- DEBORAH H TELMAN (EVP, Corporate Affairs & GC) has made 0 purchases and 3 sales selling 53,646 shares for an estimated $6,590,487.
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 17,500 shares for an estimated $2,370,865.
- JEFFREY BLUESTONE has made 0 purchases and 2 sales selling 10,000 shares for an estimated $1,242,900.
- KELLY A. KRAMER has made 0 purchases and 2 sales selling 5,611 shares for an estimated $713,186.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
GILEAD SCIENCES Hedge Fund Activity
We have seen 1,064 institutional investors add shares of GILEAD SCIENCES stock to their portfolio, and 975 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 38,953,246 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $4,781,121,414
- WELLINGTON MANAGEMENT GROUP LLP removed 9,711,230 shares (-37.9%) from their portfolio in Q4 2025, for an estimated $1,191,956,370
- BLACKROCK, INC. added 6,914,187 shares (+5.9%) to their portfolio in Q4 2025, for an estimated $848,647,312
- FMR LLC added 5,263,211 shares (+8.7%) to their portfolio in Q4 2025, for an estimated $646,006,518
- CAPITAL RESEARCH GLOBAL INVESTORS removed 4,706,975 shares (-15.7%) from their portfolio in Q4 2025, for an estimated $577,734,111
- BOSTON PARTNERS added 4,220,501 shares (+inf%) to their portfolio in Q4 2025, for an estimated $518,024,292
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 4,113,999 shares (+3763.8%) to their portfolio in Q4 2025, for an estimated $504,952,237
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
GILEAD SCIENCES Government Contracts
We have seen $14,894 of award payments to $GILD over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- LENACAPAVIR (SUNLENCA): $14,894
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
GILEAD SCIENCES Congressional Stock Trading
Members of Congress have traded $GILD stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 01/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
GILEAD SCIENCES Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/11/2026
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- Scotiabank issued a "Sector Outperform" rating on 11/13/2025
To track analyst ratings and price targets for GILEAD SCIENCES, check out Quiver Quantitative's $GILD forecast page.
GILEAD SCIENCES Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 11 analysts offer price targets for $GILD in the last 6 months, with a median target of $165.0.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $165.0 on 04/13/2026
- Matthew Harrison from Morgan Stanley set a target price of $175.0 on 04/10/2026
- Akash Tewari from Jefferies set a target price of $180.0 on 03/10/2026
- Joseph Stringer from Needham set a target price of $170.0 on 02/23/2026
- Emily Field from Barclays set a target price of $155.0 on 02/20/2026
- Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 02/11/2026
- Louis Chen from Scotiabank set a target price of $177.0 on 02/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
